Intravenous versus subcutaneous tocilizumab in Takayasu arteritis : multicentre retrospective study
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ..
OBJECTIVES: In this large multicentre study, we compared the effectiveness and safety of tocilizumab intravenous versus subcutaneous (SC) in 109 Takayasu arteritis (TAK) patients.
METHODS: We conducted a retrospective multicentre study in referral centres from France, Italy, Spain, Armenia, Israel, Japan, Tunisia and Russia regarding biological-targeted therapies in TAK, since January 2017 to September 2019.
RESULTS: A total of 109 TAK patients received at least 3 months tocilizumab therapy and were included in this study. Among them, 91 and 18 patients received intravenous and SC tocilizumab, respectively. A complete response (NIH <2 with less than 7.5 mg/day of prednisone) at 6 months was evidenced in 69% of TAK patients, of whom 57 (70%) and 11 (69%) patients were on intravenous and SC tocilizumab, respectively (p=0.95). The factors associated with complete response to tocilizumab at 6 months in multivariate analysis, only age <30 years (OR 2.85, 95% CI 1.14 to 7.12; p=0.027) and time between TAK diagnosis and tocilizumab initiation (OR 1.18, 95% CI 1.02 to 1.36; p=0.034). During the median follow-up of 30.1 months (0.4; 105.8) and 10.8 (0.1; 46.4) (p<0.0001) in patients who received tocilizumab in intravenous and SC forms, respectively, the risk of relapse was significantly higher in TAK patients on SC tocilizumab (HR=2.55, 95% CI 1.08 to 6.02; p=0.033). The overall cumulative incidence of relapse at 12 months in TAK patients was at 13.7% (95% CI 7.6% to 21.5%), with 10.3% (95% CI 4.8% to 18.4%) for those on intravenous tocilizumab vs 30.9% (95% CI 10.5% to 54.2%) for patients receiving SC tocilizumab. Adverse events occurred in 14 (15%) patients on intravenous route and in 2 (11%) on SC tocilizumab.
CONCLUSION: In this study, we confirm that tocilizumab is effective in TAK, with complete remission being achieving by 70% of disease-modifying antirheumatic drugs-refractory TAK patients at 6 months.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
RMD open - 9(2023), 2 vom: 14. Juni |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Antirheumatic Agents |
|---|
| Anmerkungen: |
Date Completed 19.06.2023 Date Revised 11.12.2023 published: Print ErratumIn: RMD Open. 2023 Jun;9(2):. - PMID 37399365 Citation Status MEDLINE |
|---|
| doi: |
10.1136/rmdopen-2022-002830 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM358232600 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM358232600 | ||
| 003 | DE-627 | ||
| 005 | 20231227131328.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/rmdopen-2022-002830 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1225.xml |
| 035 | |a (DE-627)NLM358232600 | ||
| 035 | |a (NLM)37321669 | ||
| 035 | |a (PII)e002830 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mekinian, Arsène |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Intravenous versus subcutaneous tocilizumab in Takayasu arteritis |b multicentre retrospective study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.06.2023 | ||
| 500 | |a Date Revised 11.12.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a ErratumIn: RMD Open. 2023 Jun;9(2):. - PMID 37399365 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. | ||
| 520 | |a OBJECTIVES: In this large multicentre study, we compared the effectiveness and safety of tocilizumab intravenous versus subcutaneous (SC) in 109 Takayasu arteritis (TAK) patients | ||
| 520 | |a METHODS: We conducted a retrospective multicentre study in referral centres from France, Italy, Spain, Armenia, Israel, Japan, Tunisia and Russia regarding biological-targeted therapies in TAK, since January 2017 to September 2019 | ||
| 520 | |a RESULTS: A total of 109 TAK patients received at least 3 months tocilizumab therapy and were included in this study. Among them, 91 and 18 patients received intravenous and SC tocilizumab, respectively. A complete response (NIH <2 with less than 7.5 mg/day of prednisone) at 6 months was evidenced in 69% of TAK patients, of whom 57 (70%) and 11 (69%) patients were on intravenous and SC tocilizumab, respectively (p=0.95). The factors associated with complete response to tocilizumab at 6 months in multivariate analysis, only age <30 years (OR 2.85, 95% CI 1.14 to 7.12; p=0.027) and time between TAK diagnosis and tocilizumab initiation (OR 1.18, 95% CI 1.02 to 1.36; p=0.034). During the median follow-up of 30.1 months (0.4; 105.8) and 10.8 (0.1; 46.4) (p<0.0001) in patients who received tocilizumab in intravenous and SC forms, respectively, the risk of relapse was significantly higher in TAK patients on SC tocilizumab (HR=2.55, 95% CI 1.08 to 6.02; p=0.033). The overall cumulative incidence of relapse at 12 months in TAK patients was at 13.7% (95% CI 7.6% to 21.5%), with 10.3% (95% CI 4.8% to 18.4%) for those on intravenous tocilizumab vs 30.9% (95% CI 10.5% to 54.2%) for patients receiving SC tocilizumab. Adverse events occurred in 14 (15%) patients on intravenous route and in 2 (11%) on SC tocilizumab | ||
| 520 | |a CONCLUSION: In this study, we confirm that tocilizumab is effective in TAK, with complete remission being achieving by 70% of disease-modifying antirheumatic drugs-refractory TAK patients at 6 months | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Autoimmune Diseases | |
| 650 | 4 | |a Inflammation | |
| 650 | 4 | |a Systemic vasculitis | |
| 650 | 7 | |a tocilizumab |2 NLM | |
| 650 | 7 | |a I031V2H011 |2 NLM | |
| 650 | 7 | |a Antirheumatic Agents |2 NLM | |
| 700 | 1 | |a Biard, Lucie |e verfasserin |4 aut | |
| 700 | 1 | |a Lorenzo, Dagna |e verfasserin |4 aut | |
| 700 | 1 | |a Novikov, Pavel I |e verfasserin |4 aut | |
| 700 | 1 | |a Salvarani, Carlo |e verfasserin |4 aut | |
| 700 | 1 | |a Espitia, Olivier |e verfasserin |4 aut | |
| 700 | 1 | |a Sciascia, Savino |e verfasserin |4 aut | |
| 700 | 1 | |a Michaud, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Lambert, Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Hernández-Rodríguez, José |e verfasserin |4 aut | |
| 700 | 1 | |a Schleinitz, Nicolas |e verfasserin |4 aut | |
| 700 | 1 | |a Awisat, Abid |e verfasserin |4 aut | |
| 700 | 1 | |a Puechal, Xavier |e verfasserin |4 aut | |
| 700 | 1 | |a Aouba, Achille |e verfasserin |4 aut | |
| 700 | 1 | |a Munoz Pons, Helene |e verfasserin |4 aut | |
| 700 | 1 | |a Smitienko, Ilya |e verfasserin |4 aut | |
| 700 | 1 | |a Gaultier, Jean Baptiste |e verfasserin |4 aut | |
| 700 | 1 | |a Edwige, Le Mouel |e verfasserin |4 aut | |
| 700 | 1 | |a Benhamou, Ygal |e verfasserin |4 aut | |
| 700 | 1 | |a Perlat, Antoinette |e verfasserin |4 aut | |
| 700 | 1 | |a Jego, Patrick |e verfasserin |4 aut | |
| 700 | 1 | |a Goulenok, Tiphaine |e verfasserin |4 aut | |
| 700 | 1 | |a Sacre, Karim |e verfasserin |4 aut | |
| 700 | 1 | |a Lioger, Bertrand |e verfasserin |4 aut | |
| 700 | 1 | |a Hassold, Nolan |e verfasserin |4 aut | |
| 700 | 1 | |a Broner, Jonathan |e verfasserin |4 aut | |
| 700 | 1 | |a Dufrost, Virginie |e verfasserin |4 aut | |
| 700 | 1 | |a Sené, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Seguier, Julie |e verfasserin |4 aut | |
| 700 | 1 | |a Maurier, Francois |e verfasserin |4 aut | |
| 700 | 1 | |a Berthier, Sabine |e verfasserin |4 aut | |
| 700 | 1 | |a Belot, Alexandre |e verfasserin |4 aut | |
| 700 | 1 | |a Frikha, Faten |e verfasserin |4 aut | |
| 700 | 1 | |a Denis, Guillaume |e verfasserin |4 aut | |
| 700 | 1 | |a Audemard-Verger, Alexandra |e verfasserin |4 aut | |
| 700 | 1 | |a Koné-Paut, Isabelle |e verfasserin |4 aut | |
| 700 | 1 | |a Humbert, Sebastien |e verfasserin |4 aut | |
| 700 | 1 | |a Woaye-Hune, Pascal |e verfasserin |4 aut | |
| 700 | 1 | |a Tomelleri, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Baldissera, Elena Marina |e verfasserin |4 aut | |
| 700 | 1 | |a Kuwana, Masataka |e verfasserin |4 aut | |
| 700 | 1 | |a Lo Gullo, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Mukuchyan, Vahan |e verfasserin |4 aut | |
| 700 | 1 | |a Dellal, Azeddine |e verfasserin |4 aut | |
| 700 | 1 | |a Gaches, Francis |e verfasserin |4 aut | |
| 700 | 1 | |a Zeminsky, Pierre |e verfasserin |4 aut | |
| 700 | 1 | |a Galli, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Alvarado, Moya |e verfasserin |4 aut | |
| 700 | 1 | |a Boiardi, Luigi |e verfasserin |4 aut | |
| 700 | 1 | |a Muratore, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Vautier, Mathieu |e verfasserin |4 aut | |
| 700 | 1 | |a Campochiaro, Corrado |e verfasserin |4 aut | |
| 700 | 1 | |a Moiseev, Sergey |e verfasserin |4 aut | |
| 700 | 1 | |a Vieira, Matheus |e verfasserin |4 aut | |
| 700 | 1 | |a Cacoub, Patrice |e verfasserin |4 aut | |
| 700 | 1 | |a Fain, Olivier |e verfasserin |4 aut | |
| 700 | 1 | |a Saadoun, David |e verfasserin |4 aut | |
| 700 | 0 | |a French Takayasu network |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t RMD open |d 2015 |g 9(2023), 2 vom: 14. Juni |w (DE-627)NLM254089658 |x 2056-5933 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2023 |g number:2 |g day:14 |g month:06 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/rmdopen-2022-002830 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2023 |e 2 |b 14 |c 06 | ||